ScoreComparison
Why is Bellerophon Therapeutics, Inc. ?
Unrated Stock - No Analysis Available
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Bellerophon Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals: Major should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals: Major)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
No Data Found
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
46.03%
EBIT Growth (5y)
10.94%
EBIT to Interest (avg)
-19.59
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.21
Sales to Capital Employed (avg)
1.02
Tax Ratio
12.13%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
33.30%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.04
EV to EBIT
0.45
EV to EBITDA
0.45
EV to Capital Employed
4.34
EV to Sales
-0.77
PEG Ratio
NA
Dividend Yield
2319.92%
ROCE (Latest)
973.50%
ROE (Latest)
-213.64%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bullish
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial TrendNot enough Data to analyse Financial Trend
Not enough Data to analyse Financial Trend
Here's what is working for Bellerophon Therapeutics, Inc.
Net Sales
At USD 5.64 MM has Grown at inf%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (USD MM)
Operating Cash Flow
Highest at USD -12.33 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Pre-Tax Profit
At USD -1.42 has Grown at 71.97%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
At USD -1.42 MM has Grown at 71.97%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Net Sales
Higher at USD 5.64 MM
than preceding 12 month period ended Sep 2023MOJO Watch
In the nine month period the company has already crossed sales of the previous twelve months
Net Sales (USD MM)
Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Bellerophon Therapeutics, Inc.
Cash and Eqv
Lowest at USD 15.17 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
